In pancreatic cancer cells, high expression of ST6GAL1 led to increased α-2,6 sialylation and activation of EGFR, as well as upregulation of mesenchymal markers and enhanced cell invasiveness. Here, ST6GAL1 is linked to pancreatic neoplasm.